Evidence map›Paper›PMID 29763896›Full record

ArticleActa cytologica2018

Evaluation of the HER2 and Hormone Receptor Status in Metastatic Breast Cancer Using Cell Blocks: A Multi-Institutional Study.

Rieko Nishimura, Yuya Murata, Kiyoshi Mori, Katsushige Yamashiro, Kazuya Kuraoka, Shu Ichihara, Kenichi Taguchi, Hiroyoshi Suzuki, Masahiro Ito, Natsumi Yamashita

Open access · hybridAbstract readMulticenter Study
In one paragraph

Article in Acta cytologica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 1 country.

Rieko NishimuraDepartment of Clinical Laboratory, Shikoku Cancer Center, Matsuyama, Japan.
Yuya MurataDepartment of Pathology, Tokyo Medical Center, Tokyo, Japan.
Kiyoshi MoriDepartment of Pathology, Osaka National Hospital, Osaka, Japan.
Katsushige YamashiroDivision of Pathology, Hokkaido Cancer Center, Sapporo, Japan.
Kazuya KuraokaDepartment of Diagnostic Pathology, Kure Medical Center and Chugoku Cancer Center, Kure, Japan.
Shu IchiharaDepartment of Pathology, Nagoya Medical Center, Nagoya, Japan.
Kenichi TaguchiDepartment of Pathology, Kyushu Cancer Center, Fukuoka, Japan.
Hiroyoshi SuzukiDepartment of Pathology and Laboratory Medicine, Sendai Medical Center, Sendai, Japan.
Masahiro ItoClinical Research Center, Nagasaki Medical Center, Omura, Japan.
Natsumi YamashitaDivision of Clinical Biostatistics, Section of Cancer Prevention and Epidemiology, Clinical Research Center, Shikoku Cancer Center, Matsuyama, Japan.
Nagoya Medical Center · JPKure Medical Center · JPNagasaki Medical Center · JPNational Hospital Organization Kyushu Cancer Center · JPOsaka National Hospital · JPSendai Medical Center · JPShikoku Cancer Center · JPTokyo Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveWe explore the problems associated with the cell block (CB) method for receptor analysis in breast cancer metastases and propose a method for reporting the results. STUDY

designNine institutions used the CB method for the analysis of hormone receptors (HRs) and HER2 (human epidermal growth factor receptor 2) protein in cytological specimens of breast cancer metastases in routine practice. The stained slides were independently evaluated by 8 pathologists. Dual in situ hybridization assay was performed in cases of discordant results for HER2 protein. Based on the results, we propose a method for receptor scoring in the CB method.

resultsOf 61 specimens, 57 contained tumor cells. Two or more pathologists disagreed on the results for the estrogen receptor, progesterone receptor, and HER2 protein in 3 (5.3%), 13 (22.8%), and 19 (33.3%) cases, respectively. The discrepant results for the HRs were attributed to the presence of a few positive cells or faintly stained cells. The high interobserver discordance rate for HER2 protein was explained by interobserver differences in the scoring criteria.

conclusionThe use of categorical scoring into positive and negative is recommended for evaluating the HR expressions. Use of strict criteria for HER2 protein 2+ and 3+ cases is recommended, as HER2-positive cases should not be missed.

Indexed as

Paraffin EmbeddingBiomarkers, TumorBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesFemaleHumansImmunohistochemistryIn Situ HybridizationJapanNeoplasm MetastasisObserver VariationPredictive Value of TestsReceptors, EstrogenReceptors, ProgesteroneReproducibility of ResultsTissue FixationBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneBreast cancer metastasesCell blockCytologyHER2Hormone receptors

Identifiers

PMID29763896
PMCPMC6159834
OpenAlexW2803969133

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.